Detailed information for compound 82475
Basic information
Technical information
- TDR Targets ID: 82475
- Name: [1-phosphono-2-(pyridin-2-ylamino)ethyl]phosp honic acid
- MW: 282.128 | Formula: C7H12N2O6P2
-
H donors: 5
H acceptors: 7
LogP: -1.77
Rotable bonds: 5
Rule of 5 violations (Lipinski): 1 - SMILES: OP(=O)(C(P(=O)(O)O)CNc1ccccn1)O
- InChi: 1S/C7H12N2O6P2/c10-16(11,12)7(17(13,14)15)5-9-6-3-1-2-4-8-6/h1-4,7H,5H2,(H,8,9)(H2,10,11,12)(H2,13,14,15)
- InChiKey: BHVCADPDEFLLGM-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- [1-phosphono-2-(2-pyridylamino)ethyl]phosphonic acid
- 105462-22-4
- 1BY
- [2-(2-pyridinylamino)ethylidene]-1,1-bisphosphonate (hydrate)
- NSC724480
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | farnesyl diphosphate synthase | Starlite/ChEMBL | References |
| Leishmania donovani | farnesyl pyrophosphate synthase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Plasmodium vivax | geranylgeranyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Trypanosoma cruzi | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
| Loa Loa (eye worm) | polyprenyl synthetase | 0.0247685 | 0.5 | 0.5 |
| Echinococcus granulosus | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Trichomonas vaginalis | geranylgeranyl diphosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
| Giardia lamblia | Farnesyl diphosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Mycobacterium tuberculosis | Probable geranylgeranyl pyrophosphate synthetase IdsA2 (ggppsase) (GGPP synthetase) (geranylgeranyl diphosphate synthase) | 0.0247685 | 0.5 | 0.5 |
| Trypanosoma brucei | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Schistosoma mansoni | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Toxoplasma gondii | polyprenyl synthetase superfamily protein | 0.0247685 | 0.5 | 0.5 |
| Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Plasmodium falciparum | geranylgeranyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
| Trypanosoma cruzi | farnesyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
| Mycobacterium ulcerans | geranylgeranyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Brugia malayi | Polyprenyl synthetase family protein | 0.0247685 | 0.5 | 0.5 |
| Leishmania major | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Echinococcus multilocularis | farnesyl pyrophosphate synthase | 0.0247685 | 0.5 | 0.5 |
| Trichomonas vaginalis | geranylgeranyl pyrophosphate synthase, putative | 0.0247685 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| ED50 (functional) | = 144 uM | Dose of the compound to inhibit the growth of human KB carcinoma cell line | ChEMBL. | 16162013 |
| ED50 (functional) | = 144 uM | Dose of the compound to inhibit the growth of human KB carcinoma cell line | ChEMBL. | 16162013 |
| IC50 (binding) | = -6.77 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
| IC50 (functional) | = 4.6 | Growth inhibition of Plasmodium falciparum | ChEMBL. | 19053772 |
| IC50 (binding) | > 1 mM | Inhibition of Aquifex aeolicus IspH expressed in Escherichia coli BL21 (DE3) using HMBPP substrate | ChEMBL. | 20426416 |
| IC50 (binding) | = 15 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins | ChEMBL. | 18327899 |
| IC50 (binding) | = 15 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins | ChEMBL. | 18327899 |
| IC50 (binding) | = 190.1 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 | ChEMBL. | 18327899 |
| IC50 (binding) | = 190.1 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 | ChEMBL. | 18327899 |
| IC50 (binding) | = 0.17 uM | Inhibitory activity against Leishmania major Farnesyl diphosphate synthase | ChEMBL. | 14695831 |
| IC50 (binding) | = 0.17 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
| IC50 (binding) | = 0.17 uM | Inhibitory activity against Leishmania major Farnesyl diphosphate synthase | ChEMBL. | 14695831 |
| IC50 (binding) | = 0.17 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
| IC50 (functional) | = 4.8 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release | ChEMBL. | 14711309 |
| IC50 (functional) | = 14 uM | Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
| IC50 (functional) | = 15 uM | Ability to inhibit growth of D. discoideum. | ChEMBL. | 12086477 |
| IC50 (functional) | = 15 uM | Ability to inhibit growth of D. discoideum. | ChEMBL. | 12086477 |
| IC50 (functional) | = 17 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
| IC50 (functional) | = 17 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
| IC50 (functional) | = 17 uM | Antimicrobial activity against Plasmodium falciparum | ChEMBL. | 20185316 |
| IC50 (functional) | = 28 uM | Growth inhibition of Plasmodium falciparum | ChEMBL. | 19053772 |
| IC50 (functional) | = 63.7 uM | Antiproliferative activity against human NCI-H460 cell line by MTT assay | ChEMBL. | 16970405 |
| IC50 (functional) | = 63.7 uM | Antiproliferative activity against human NCI-H460 cell line by MTT assay | ChEMBL. | 16970405 |
| IC50 (functional) | = 147 uM | Antiproliferative activity against human SF-268 cell line by MTT assay | ChEMBL. | 16970405 |
| IC50 (functional) | = 147 uM | Antiproliferative activity against human SF-268 cell line by MTT assay | ChEMBL. | 16970405 |
| IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
| IC50 (functional) | > 200 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
| IC50 (functional) | = 200 uM | Antimicrobial activity against Entamoeba histolytica | ChEMBL. | 20185316 |
| IC50 (functional) | = 223 uM | Antiproliferative activity against human MCF7 cell line by MTT assay | ChEMBL. | 16970405 |
| IC50 (functional) | = 223 uM | Antiproliferative activity against human MCF7 cell line by MTT assay | ChEMBL. | 16970405 |
| IC50 (binding) | = 383.3 uM | Inhibition of recombinant trypanosoma brucei soluble vacuolar pyrophosphatase expressed in escherichia coli | ChEMBL. | 16162013 |
| IC50 (binding) | = 383.3 uM | Inhibition of recombinant trypanosoma brucei soluble vacuolar pyrophosphatase expressed in escherichia coli | ChEMBL. | 16162013 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli W3110 | ChEMBL. | 17149863 |
| IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli W3110 | ChEMBL. | 17149863 |
| Ki (binding) | = 2.3 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins | ChEMBL. | 18327899 |
| Ki (binding) | = 2.3 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins | ChEMBL. | 18327899 |
| Ki (binding) | = 36.9 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 | ChEMBL. | 18327899 |
| Ki (binding) | = 36.9 nM | Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 | ChEMBL. | 18327899 |
| Ki (binding) | = 0.016 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
| Ki (binding) | = 0.016 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
| LD50 (ADMET) | = 144 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
| LD50 (ADMET) | = 144 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
| LED (functional) | = 0.01 mg kg-1 | Inhibition of bone resorption in rat assessed as phosphate | ChEMBL. | 18327899 |
| LED (functional) | = 0.01 mgP kg-1 | Bone resorption activity in rats. | ChEMBL. | 12086477 |
| Log IC50 (functional) | = 4.84 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL | ChEMBL. | 14711309 |
| Log IC50 (functional) | = 5.31 | pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release | ChEMBL. | 14711309 |
| Log IC50 (binding) | = 6.77 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
| TI (functional) | = 0.4 | Ratio of ED50 against KB cell line to that of IC50 of TbVSP1 | ChEMBL. | 16162013 |
| TI (functional) | = 0.4 | Ratio of ED50 against KB cell line to that of IC50 of TbVSP1 | ChEMBL. | 16162013 |
| TI (ADMET) | = 5.12 | Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Plasmodium falciparum | ChEMBL. | 14695831 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Plasmodium falciparum | ChEMBL23 | 14695831 | |
| Dictyostelium discoideum | ChEMBL23 | 12086477 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL294192
- PubChem: 406401
Bibliographic References
8 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.